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stem celThe evolving biology of cell reprogrammingIan Wilmut*, Gareth Sullivan and Ian Chambers
MRC Centre for Regenerative Medicine, University of Edinburgh, Chancellor’s Building,
49 Little France Crescent, Edinburgh, EH16 4SB, Scotland, UK
Modern stem cell biology has achieved a transformation that was thought by many to be every bit as
unattainable as the ancient alchemists’ dream of transforming base metals into gold. Exciting oppor-
tunities arise from the process known as ‘cellular reprogramming’ in which cells can be reliably
changed from one tissue type to another. This is enabling novel approaches to more deeply inves-
tigate the fundamental basis of cell identity. In addition, new opportunities have also been created to
study (perhaps even to treat) human genetic and degenerative diseases. Specific cell types that are
affected in inherited disease can now be generated from easily accessible cells from the patient and
compared with equivalent cells from healthy donors. The differences in cellular phenotype between
the two may then be identified, and assays developed to establish therapies that prevent the devel-
opment or progression of disease symptoms. Cellular reprogramming also has the potential to create
new cells to replace those whose death or dysfunction causes disease symptoms. For patients suffer-
ing from inherited cases of degenerative diseases like Parkinson’s disease or amyotrophic lateral
sclerosis (also known as motor neuron disease), the future realization of such cell-based therapies
would truly be worth its weight in gold. However, before this enormous potential can become a rea-
lity, several significant biological and technical challenges must be overcome. Furthermore, to
maintain the credibility of the scientific community with the general public, it is important that
hope-inspiring advances are not over-hyped. The papers in this issue of the Philosophical Transactions
of the Royal Society B: Biological Sciences cover many areas relevant to this topic. In this Introduction,
we provide an overall context in which to consider these individual papers.
Keywords: stem cells; regenerative medicine; pluripotency; reprogramming; disease modelling;
transcription factors1. INTRODUCTION
During the past 50 years, a number of key experiments
have shown that cell fate is much less rigidly fixed than
previously understood. The experimental approaches
that were used in these studies included somatic cell
nuclear transfer (SCNT) [1,2], cell fusion [3], intro-
duction of selected transcription factors [4] or of
extracts [5]. This stream of research culminated six
years ago when it was established that after the intro-
duction of key transcription factors into somatic
cells, a small proportion acquired the characteristics
of an embryonic stem (ES) cell [6]. These cells are
known as induced pluripotent stem or iPS cells. The
term ‘reprogramming’ has been used to describe the
above experiments in a number of different contexts
and this has become confusing. In this review,
‘factor-directed reprogramming’ will indicate that
transcription factors have been introduced into cells
to induce them to revert to an earlier stage of deve-
lopment. Cells turned back to an earlier stage of
development in this way are said to be ‘reprogrammed’r for correspondence (ian.wilmut@ed.ac.uk).
tribution of 15 to a Discussion Meeting Issue ‘What next for
l biology? The evolving biology of cell reprogramming’.
2183while the process is described as ‘reprogramming’. By
contrast, the use of this approach to change the fate of
the cell to another lineage will be termed ‘directed fate
conversion’. This is in contrast to ‘directed differen-
tiation’ when treatment induces cells to convert to
their natural progeny.
The discovery that factor-directed reprogramming
could convert somatic cells to pluripotent cells,
which are potentially capable of forming any tissue in
the body, had a seismic effect on stem cell biology
and its potential applications. The establishment of
these procedures depended upon some knowledge of
the molecular mechanisms that specify and maintain
pluripotent cell identity to suggest candidate transcrip-
tion factors that might bring about the desired change.
The initial protocols have been adapted and refined
and although factor-directed reprogramming to pluri-
potency is now routine, it remains an inefficient,
slow process. A deeper understanding of the mechan-
isms that maintain pluripotency and of those involved
in the process of this change can be expected to con-
tinue to lead to improvements in the procedures.
Our understanding of the abilities and limits of
factor-directed reprogramming exemplified by induced
pluripotency has evolved at a mind-boggling pace.
Since that seminal discovery, new experiments haveThis journal is q 2011 The Royal Society
2184 I. Wilmut et al. Introduction. Evolving biology of cell reprogrammingseen factor-directed reprogramming of many different
cell types, as well as the direct fate conversion of fibro-
blasts to other non-pluripotent cell types, including
neurons and cardiomyocytes. Moreover, the appli-
cation of these procedures to the study of human
disease has resulted in significant insights into disease
ontology brought about through the production of
patient-specific induced pluripotent cells. The papers
in this issue of the Philosophical Transactions of the
Royal Society B: Biological Sciences cover many areas
relevant to this fascinating new research. In this Intro-
duction, we provide an overall context in which to
consider these individual papers.2. FACTOR-DIRECTED REPROGRAMMING TO
PLURIPOTENCY
Pluripotency is the ability of a cell to differentiate into
cell types representative of each of the primary embryo-
nic germ layers. A new research era was launched when
Takahashi & Yamanaka [6] demonstrated that, follow-
ing enforced expression of four transcription factors
normally expressed in pluripotent cells (Oct4, Sox2,
Klf4 and c-Myc), a small proportion of differentiated
cells can be induced to adopt a phenotype similar to
ES cells; these are called iPS cells. This initial exper-
iment with mouse foetal fibroblasts was quickly
extended to many different adult mouse cell types—
(liver and stomach [7]; B-lymphocytes [8]; adult
neural cells [9]). Three independent groups exempli-
fied this in human cells [10–12]. These or very
similar methods are now used routinely in many differ-
ent laboratories around the world. Since the initial
reports, a number of other genes that contribute to
this reprogramming process have been identified. In
some cases, these are able to replace one of the four fac-
tors identified by Yamanaka (often referred to as the
Yamanaka factors), while in others they complement the
standard protocol. This topic is reviewed by Okita &
Yamanaka [13] in this issue.
Oct4, Sox2, Klf4 and c-Myc, were originally intro-
duced using retroviral vectors [6]. While the
procedure is very repeatable, it has several limitations.
Namely, it is slow, requiring three to five weeks or
more for colonies of apparently pluripotent cells to
be available for passage, and only a small proportion
of treated cells become pluripotent [14]. More impor-
tantly, the viral integrants in the pluripotent cells carry
the risk of causing harmful mutations. In addition,
c-Myc is an oncogene and caused tumours in 20 per
cent of animals when iPS cells were introduced into
chimeras [15]. Ideally, the retroviral vectors in iPS
cells are silenced allowing the endogenous regulatory
mechanisms to function and control the balance
between pluripotency and differentiation. However,
as a practical matter, it is important to demonstrate
that this retroviral gene silencing has occurred and is
maintained after differentiation; otherwise, the trans-
genes may interfere with the normal physiological
function of the cells.
Empirical attempts to overcome these limitations
are described in table 1 and are further discussed by
Okita & Yamanaka [13]. The PiggyBac vector has
been used to introduce all four proteins in a singlePhil. Trans. R. Soc. B (2011)transcript [19]. This modified transposon has the
advantage that, in principle, it can be removed from
iPS cells at the end of the treatment without any
mutation. A number of non-integrating vectors have
been used, including Sendai virus [31,39]. This RNA
virus carries no risk of altering the host genome, infects
a great variety of different cell types, can accommodate
the four gene-coding sequences and can be completely
removed from the iPS cells. Advantage has also been
taken of the fact that some cell types express one or
more of the Yamanaka factors. In this way, iPS cells
were obtained from murine neural stem cells, which
express Sox2 and c-Myc, by introducing Oct4 alone
[40]. It was also notable that the conversion of neural
stem cells was quicker than that of fibroblasts, demon-
strating that the nature of the somatic cell influenced
the efficiency of iPS cell production [9,41].
In part, the inefficiency of Yamanaka’s procedure is
owing to sub-optimal expression of the transgenes
[42]. This was demonstrated by comparing iPS cell
production efficiencies between a conventional pro-
cedure and one in which somatic cells derived from
iPS cells were reprogrammed for a second time. This
is known as ‘secondary reprogramming’. In both
cases, doxycycline was used to turn-on the expression
of the four vectors, but while the location and number
of viral inserts were variable in primary somatic cells,
the expression of the viral inserts in the secondary
line was uniform and known to be effective [42].
The efficiency of iPS cell production was between
25- and 50-fold greater in secondary fibroblasts than
after primary infection. This seems to indicate that
in some cases an inadequate number of copies of the
genes insert or that random integration may take
place at inappropriate sites and suggests that other
approaches such as exposure to small molecules,
proteins or mRNA could be more efficient and/or
more reproducible. Introduction of modified mRNA
encoding the four Yamanaka genes, but with OCT4
at higher levels, was more efficient and quicker than
the standard use of retroviral vectors [38]. Modified
ribonucleoside bases incorporated into the synthesized
mRNA were designed to reduce the innate anti-viral
immune response and increase cell viability and
enabled them to direct reprogramming by daily trans-
fection. Further studies are required to confirm that
this procedure is repeatable and effective in different
cell types.
Effective selection of small molecules to manipulate
complex process such as factor-directed reprogramming
is a major challenge, but significant progress has been
made as discussed by Efe & Ding [43] in this issue.
‘Pluripotin’ is a compound that maintains mouse ES
cells in a pluripotent state through many passages in
the absence of feeders, serum or cytokine. This effect
was later shown through action on ERK1 (extra-
cellular-signal-regulated kinase 1) and RasGAP (Ras
GTPase activating protein); the authors comment that
the use of small molecules established more stable
and uniform populations of cells. With regard to
factor-directed reprogramming, the combined inhi-
bition of the ERK1 pathway and glycogen synthase
kinase 3 (GSK3) has been shown to promote factor-
induced reprogramming to a basal ‘ground state’ [41].
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2186 I. Wilmut et al. Introduction. Evolving biology of cell reprogrammingAdditional compounds that have global effects upon
chromatin organization may facilitate the effect of intro-
duced proteins. Compounds that are effective in some
circumstances include valproic acid and butyrate
(inhibitors of histone deacetylase), RG108 (a DNA
methyltransferase inhibitor) and parnate (an H3K4 his-
tone demethylase inhibitor). Other compounds are able
to replace specific factors (see Efe & Deng [43]). Most
strikingly, a combination of three inhibitors increased
the efficiency of reprogramming of human fibroblasts
by the four Yamanaka factors by 200-fold [44]. It is a
particular challenge to replace all of the transcription
factors with small molecules, but human fibroblasts
have been reprogrammed effectively by Oct4 and a
cocktail of chemicals [45].3. DIRECTED FATE CONVERSION TO A
DIFFERENT SOMATIC CELL TYPE
A landmark experiment in the molecular basis of cell
identity was performed over 25 years ago, when gene-
transfer experiments showed that ectopic expression
of the transcription factor MYOD was sufficient to
convert fibroblasts to muscle fibres [4]. Inspired by
these experiments and by the new methods for the pro-
duction of pluripotent stem cells, the possibility of
inducing fibroblasts to acquire the characteristics of
neurons [46] or cardiomyocytes has been investigated
[47]. Both groups selected transcription factors that
are specifically expressed in the target tissues, have
known roles in differentiation to the target tissue or
are known to promote epigenetic changes. Initially, 19
[46] or 14 [47] transcription factors were examined
for their ability to activate tissue-specific reporters as
the basis for their selection protocol. The same reduc-
tionist strategy successfully deployed by Takahashi &
Yamanaka was then used in which transcription factors
were removed from the pool individually to define the
minimum effective group.
Together, Brn2, Myt1l, Zic1, Olig2 and Ascl1 were
able to induce the change to a neural phenotype. Imma-
ture neurons were seen three days after the treatment
of mouse embryonic fibroblasts (MEFs) and by day 5
neuronal cells with long branching processes were
present. Although tail tip fibroblasts did not exhibit com-
parable neuronal cells before day 12, final efficiency of
conversion was comparable, being 1–8% with both
MEFs and tail tip fibroblasts. Further analysis demon-
strated that Ascl1 was sufficient to induce formation of
immature neurons, but that inclusion of Brn2 and
Myt1 generated mature neurons with efficiencies of up
to approximately 20 per cent. Neurons from both
donor cells types were able to form synapses and express
markers of cortical identity. A low proportion of induced
neuronal cells expressed markers of GABAergic neur-
ons. Further research is required to identify protocols
that lead to the formation of other neural cell types.
The reporter gene was activated in over 20 per cent of
cardiac fibroblasts when Gata4, Mef2c, Mesp1 and Tbx5
were introduced [47]. Subsequent analyses established
that Mesp1 was not essential. Detailed analyses of the
chromatin of the cells showed that fate change induced
by the pool of three genes had altered their epigenetic
status to be very similar to that of cardiomyocytes.Phil. Trans. R. Soc. B (2011)Interestingly, monitoring gene expression following this
fate change established that during this process none of
the reprogrammed cells passed through a progenitor
state. The same pool of three genes was able to direct a
fate change of tail tip fibroblasts, although there were
some differences in the nature of the cardiomyocytes
that were induced. A small proportion of the cardiomyo-
cytes derived from cardiac fibroblasts (1%) showed the
electrophysiological and beating characteristics of
cardiomyocytes.
A different approach to direct fate change of
somatic cells depended upon the observation that
during derivation of iPS cells, colonies were present
with a round morphology that resembled that of
haematopoietic cells [48]. In subsequent analysis,
forced expression of OCT4 alone made it possible to
isolate CD45 haematopoietic progenitors from pri-
mary human fibroblast cultures. The subsequent fate
of these cells depended upon the culture environment;
under appropriate conditions, multipotent haemato-
poietic progenitors able to form cells of the myeloid,
erythroid and megakaryocytic lineages were obtained
without first becoming iPS cells.4. MECHANISMS THAT UNDERPIN
PLURIPOTENCY
Since pluripotent stem cells were first cultured in 1967
[49], much has been learned about the mechanisms
that maintain pluripotency [50,51]. Early lessons led to
the direct isolation of ES cells from mouse embryos
[52,53]. The subsequent isolation of human ES cells
[54] highlighted notable differences between mouse
and human ES cells in morphology and in growth
factor requirements. The more recent establishment of
pluripotent cell lines from the post-implantation mouse
epiblast (known as epiblast stem cells or EpiSCs) that
resemble human ES cells in growth factor requirements
and gene expression has raised the possibility that,
although derived from pre-implantation embryos,
human ES cells may be most closely related to the
post-implantation human epiblast. The recent establish-
ment of EpiSCs from pre-implantation mouse embryos
cultured in human ES cell culture conditions adds
weight to this proposition [55,56].
Ordinarily, mouse ES cells require the combined
actions of leukaemia inhibitory factor (LIF) and bone
morphogenetic protein (BMP) to remain in a pluripotent
state [57]. However, LIF and BMP can be dispensed with
provided the cells are treated with inhibitors of particular
signalling pathways [58]. Inhibition of the mitogen-acti-
vated protein kinase (ERK1/2) pathway as well as
inhibition of GSK3 is able to maintain pluripotency.
These results indicate that shielding mouse ES cells
from pro-differentiative signals enables the stabilization
of the pluripotent phenotype and has been interpreted
to indicate that cells cultured in this way are in a basal
‘ground state’ in which they can propagate indefinitely
provided they are insulated from signalling pathways.
However, the possibility remains that undetected auto-
crine signals may be required to maintain the cells in an
undifferentiated state.
As well as signalling requirements, particular tran-
scription factors have important roles in maintaining
Introduction. Evolving biology of cell reprogramming I. Wilmut et al. 2187pluripotency. Three of the most critical factors are
Oct4, Sox2 and Nanog. Expression of Oct4 is required
for the initial specification of pluripotent cells in vivo
[59]. Maintenance of the pluripotent state depends
on keeping Oct4 expression between upper and
lower limits; loss of expression leads to trophectoderm
differentiation [59,60] while a higher level induces
differentiation to mesoderm and endoderm [60].
Sox2 is required for epiblast maintenance [61] and
acts upon many of the same target genes as Oct4 by
binding to DNA sequences adjacent to the Oct4
binding site [62]. The level of expression of Nanog
determines self-renewal in mouse ES cells as overex-
pression renders the cells independent of cytokine
[63]), while reduced expression causes a reduction in
self-renewal efficiency [64]. Nanog is also required
for pluripotent cell specification both during develop-
ment and in the final stages of reprogramming to
‘ground state’ pluripotency [65]. This requirement is
discussed in the paper by Theunissen & Silva [66] in
this issue. Nanog is also needed to allow the completion
of primordial germ cell development [64]. This dual
requirement is interesting in view of the two waves of
epigenetic change that occur at the blastocyst stage
and during primordial germ cell development. The
confluence and overlap in mechanisms occurring
during these processes is the subject of the paper from
Hajkova [67] in this issue.
Muchof the present understanding of the mechanisms
that regulate pluripotency or initiate differentiation has
been gleaned by manipulating and observing a very
small number of genes. In contrast, new studies that
monitor changes in thousands of genes and use bio-
informatics tools to identify interactions between genes
are revealing large networks of interactions [62,68].
Genome-wide chromatin immunoprecipitation (ChIP)
has been used extensively to identify transcriptional net-
works. Oct4, Sox2 and Nanog have feedback effects
upon one another and they co-bind to promoters of
many genes [69,70]. Moreover, many genomic sites to
which Oct4, Sox2 and Nanog are co-localized also bind
additional pluripotency transcription factors, suggesting
that extensive combinatorial regulation of transcription
underpins stable pluripotent cell identity [71,72]. Down-
stream genes include members of signalling networks,
chromatin-remodelling proteins and micro-RNAs that
are hypothesized to maintain pluripotency while also
inhibiting differentiation.
While both mouse and human ES cells have tran-
scriptional networks based around Oct4 (OCT4), Sox2
(SOX2) and Nanog (NANOG), differences between
the species emphasize the idea that human ES cells
are more like mouse EpiSCs than mouse ES cells
[73]. In addition, protein interaction analyses are reveal-
ing associations between critical protein components in
the network [74–77]. While all the above studies are
important for generating hypotheses, many of the
measurements have the limitation that they are snap-
shots of a fixed moment and thus operate as
population averages, ignoring potentially functional vari-
ation within apparently homogeneous cell populations.
ES cells in culture show a marked variability in the
expression of some key regulatory genes, including
pluripotency genes such as Nanog, and Sox2, as wellPhil. Trans. R. Soc. B (2011)as lineage-affiliated genes such as T-brachyury and
Hex as discussed by Osorno & Chambers [78] in this
issue. Cells that express low levels of Nanog can
revert to a high Nanog-expressing state, but are also
more prone to differentiate. This has led to the
hypothesis that heterogeneity allows differentiation to
proceed while retaining a pluripotent population
[64]. This idea is pursued in relation to the transition
of ES cells to EpiSCs by Osorno & Chambers.
In this issue, Huang [79] discusses such heterogen-
eity using mathematical representations of cell
identities in terms of the quantitative state of gene
expression in a cell at a given time. While many poss-
ible combinations of individual gene expression states
appear combinatorially possible, only a subset of
these exists in reality. Furthermore, cells expressing
similar levels of pluripotency genes may have reached
that position from different starting points and be on
different trajectories [79].5. CHANGES DURING INDUCED PLURIPOTENT
STEM CELL DERIVATION
In these circumstances, it is perhaps not surprising
that there is considerable variation between cells in
response to factor-induced reprogramming. Among
fibroblasts selected initially as all having a high level
of expression of Thy1 as a marker of fibroblast pheno-
type, roughly half the cells had lost Thy1 after five days
of treatment, but only a small proportion of these cells
become fully reprogrammed iPS cells [80]. By con-
trast, extended induction of transgene expression for
several weeks suggests that most, if not all, cells have
the ability to become iPS cells [81]. This difference
between the initial reaction and the final response to
prolonged treatment has been interpreted to indicate
stochastic variation between cells in the precise
exposure to reprogramming factors or in the ability
of the cells to respond to those factors. Sequential
detailed analyses of cells during the process of
reprogramming can identify the population that is
being successfully reprogrammed and so provide
information on how to improve the procedure.
During secondary reprogramming of fibroblasts,
expression of mesenchymal genes was reduced by
5–40-fold in four days along with the induction of
genes concerned with proliferation. Variation in gene
expression was observed in lines established after suc-
cessful reprogramming, but in general they had
become very similar to ES cells. Partially reprogrammed
cells derived from foetal fibroblasts or B-lymphocytes
showed incomplete inhibition of different lineage-
specific genes and DNA hypermethylation of loci
associated with pluripotency [82]. These observations
led to the hypotheses that partial reprogramming might
reflect inadequate inhibition of transcription factors
associated with the somatic cell phenotype and failure
to fully demethylate lineage-specific genes. Indeed, the
efficiency of reprogramming was increased using RNAi
to reduce the level of key transcription factors and of
small molecules to promote demethylation [82].
Direct analysis of chromatin changes in secondary
MEFs during the first days after induction of transgene
expression is possible by careful monitoring of cell
2188 I. Wilmut et al. Introduction. Evolving biology of cell reprogrammingdivision in secondary somatic cells that carry inducible
vectors [83]. The predominant initial change was to
silence somatic genes rather than activate pluripotency
genes and this effect increased gradually with
additional cell divisions. Rapid, genome-wide changes
in the permissive histone modification, H3K4me2,
were observed at large numbers of loci, including
large numbers of genes related to pluripotency or regu-
lation of development. Interestingly, these changes
often preceded the change in gene expression and
occurred in cells that had not yet divided. These
results reveal an unexpected chromatin-remodelling
effect of the reprogramming factors that precedes tran-
scriptional activation of ES cell-specific genes.
High-resolution, time-lapse imaging technology has
also been used to identify retrospectively those cells
from which iPS cell colonies were derived following the
treatment of secondary somatic cells carrying doxycycline
inducible vectors described above [84]. Strikingly, all iPS
cell colonies arose from small, fast-dividing cells that first
became apparent soon after induction. These cells had a
cell cycle length of 12.2+2.8 h after the first division,
which was strikingly shorter than that of published figures
for embryonic fibroblasts (18–22 h), but very similar to
that of murine ES cells (11–16 h). The fact that all of
the iPS cells were derived from the small cells emphasizes
the importance of this early change and argues in favour of
there being a single important step at this stage. It will be
interesting to see how this can be resolved with the model
which is often accepted of an unpredictable, inefficient
progress through several independent steps—the stochas-
tic model of iPS cell production.6. MOLECULAR MECHANISMS OF
REPROGRAMMING IN OTHER MODEL SYSTEMS
In addition to direct observations during iPS cell
production, four other model systems have provi-
ded insight into molecular mechanisms of cellular
de-differentiation. These are SCNT, exposure of mam-
malian somatic nuclei to amphibian oocyte cytoplasm,
analysis of epigenetic changes during the development
of germ cells and cell fusion. It is noteworthy that
studies in all four situations describe rapid changes in
chromatin structure including DNA methylation, but
the mechanisms remain to be fully understood.
Following the transfer of nuclei into enucleated
oocytes, direct observation by immunohistochemistry
demonstrated major changes in DNA methylation and
histone modifications within hours of nuclear trans-
fer [85]. Early experiments demonstrated dramatic
reductions in the expression of genes associated with
the somatic donor cells by the blastocyst stage [86,87].
However, recent work has shown that even at this
stage of development, abnormalities of gene expression
were present in most of the 87 individually analysed
murine blastocysts [88]. In this study, nuclei from Ser-
toli cells, cumulus cells and ES cells were compared
and characteristic perturbations to gene expression
were apparent in the three groups of embryos. Repres-
sion of gene expression was by far the more common
perturbation with expression of seven genes depressed
in embryos derived from all three different donor cell
types—Asz1, Magea5, Magea3, Xlr3a, Xlr5c, Hemt1Phil. Trans. R. Soc. B (2011)and Tktl1. These genes may be suitable early markers
of successful reprogramming after nuclear transfer as
their normal expression in cloned embryos was associ-
ated with the most nearly normal overall pattern of
gene expression.
An alternative system for analysis of reprogramming
events after nuclear transfer is to follow the changes in
the nuclei of mammalian somatic cells injected intoXeno-
pusoocytes [89,90]. In theXenopus system, large numbers
of nuclei can be studied, with a majority of them being
within the germinal vesicle [91]. Transplanted nuclei
begin transcribing pluripotency genes within 24–72 h,
depending upon the stage of development from which
the cell was obtained. ChIP assays revealed an increase
in histone H3 lysine 4 dimethylation (H3K4me2) in the
regulatory and coding regions of pluripotency genes in
reprogrammed nuclei. Interestingly, the extent of histone
H3 lysine 4 trimethylation (H3K4me3) varied and was
concluded to be a function of the timing of reprogram-
ming. H3K4me3 was not at all seen on genes such as
b-globin that are not transcribed, but was present on plur-
ipotency genes in some nuclei [89].
There is some evidence that axolotl oocyte cytoplasm
has a greater ability than that of Xenopus to remodel
mammalian chromatin [92]. There were dramatic
changes in gene expression within 6 h of treatment in
breast cancer cells permeabilized before immersion in
extract, including the expression of some genes that
were silenced in the cell line. This expression occurred
without DNA replication, and was associated with
demethylation of DNA and removal of repressive his-
tone marks at the promoters of tumour suppressor
genes. This remodelling activity was found only in pro-
phase oocytes and not in extracts from ovulated eggs.
Furthermore, a similar activity was present in only
limited amounts in mouse ES cell extracts [92,93].
These studies in amphibians provide opportunities for
identifying additional factors that might be used in
factor-directed reprogramming protocols.
In addition to DNA demethylation during the for-
mation of pronuclei referred to above, similar
changes occur during the development of primordial
germ cells and this, too, is amenable to manipulation
and analysis. At both of these stages, components of
the base excision DNA repair (BER) pathway accumu-
late at the time of DNA demethylation and molecular
inhibitors of the BER pathway prevent DNA demethy-
lation in germ cells [93], suggesting that this pathway
may have a role in demethylation. Changes in DNA
methylation are associated with the loss of repres-
sive histone modifications, such as H3K9me3 and
H3K7me3 and it has been proposed that these
marked changes in chromatin structure may reflect dis-
assembly and rebuilding of chromatin, rather than the
action of several histone modification enzymes [67].
When human somatic cells are fused to murine
ES cells, in some cases, gene expression of the
human nucleus is modified to closely resemble that
of human ES cells. Indeed, expression of key pluripo-
tency genes is initiated within 24 h [94]. Use of this
approach to analyse mechanisms of reprogramming
is discussed by Piccolo and colleagues [95] in this
issue. Conversely, expression of tissue-specific genes
is significantly reduced within 48 h. All of these
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which are known as heterokaryons. If the nuclei are
removed from ES cells before fusion of the cytoplast
to the human somatic cell, the degree of nuclear re-
modelling is greatly reduced [96]. Following fusion
of human B cells to mouse ES cells, approximately
15 per cent of the heterokaryons express SSEA4 and
other cell surface markers of pluripotency. This
approach can be used to select those cells that express
the pluripotency genes OCT4, CRIPTO and NANOG
[94,97]. It is then possible to search for the key
molecular mechanisms that bring about remodelling
[98]. Oct4 and the remodelling complexes PRC1/
PRC2 are all essential for reprogramming to pluri-
potency. Oct4 protein from the mouse ES cell
migrates into the human nucleus over the period of
6–34 h during which the volume of the nucleus swells
by approximately 2.5-fold, although these changes are
not themselves predictive of successful reprogramming.
Other changes that were associated with successful
remodelling include an increase in the level of phos-
phorylated histone H3 at serine 10 (H3S10ph) and the
re-distribution of heterochromatin protein 1 (HP1a)
in human nuclei. Inhibition of phosphorylation of
H3S10 dramatically reduced H3S10ph levels in human
B cell nuclei, and prevented HP1a redistribution, but
did not abolish successful reprogramming. This result
suggests that although changes in H3S10ph and HP1a
characterize reprogrammed cells, neither is essential for
successful reprogramming to pluripotency and it con-
trasts with the observations of changes in these proteins
in the nuclei incubated in Xenopus oocytes [89].
Together, these different observations reveal that
reprogramming as achieved by the four Yamanaka fac-
tors is slow and particularly inefficient in comparison
with the changes in these other model systems. It is per-
haps unsurprising that exposure of a somatic nucleus to
the complex mileu of an oocyte cytoplasm or a pluripo-
tent cell would result in a more rapid change than can be
achieved by merely adding four transcription factors.
It is possible that differences in the concentration of
the active agents in relation to the quantity of chromo-
somes are contributory. Alternatively, reprogramming
by transcription factors may appear more passive
compared to exposure to extracts because following
expression, transcription factors must accumulate and
be formed into effective multi-protein complexes in
order to function. In addition, the more rapid repro-
gramming may reflect the action of other factors that
are present in oocyte or ES cell cytoplasm that have
not yet been identified.
A recent search for such factors identified components
of the ATP-dependent Brahma (or Brahma-related-gene
1)-associated factor (BAF) chromatin-remodelling
complex as being able to significantly increase the repro-
gramming efficiency of fibroblasts by the four Yamanaka
factors. These observations are interesting given the role
of an ES cell form of BAF in maintaining pluripotency
[99–101] and the detection of Brg1 and Baf155 in Oct4
protein complexes [76]. This may suggest that BAF acts
by facilitating chromatin binding of Oct4 to promoters
during factor-directed reprogramming. It remains to be
seen if this effect can be confirmed and extended by the
identification of other factors.Phil. Trans. R. Soc. B (2011)7. THE ACCURACY OF FACTOR-DIRECTED
REPROGRAMMING
While it was immediately obvious that profound
changes had been induced in iPS cells, it is always
important to assess the accuracy of reprogramming by
a number of different measures. These may include
confirming the presence of key markers of cell iden-
tity, genome-wide measures of gene expression and
epigenetic status, or confirmation of appropriate phys-
iological function. A brief survey of the literature
revealed differences in gene expression between pluri-
potent stem cell populations [102]. In some cases,
the abnormal pattern of gene expression suggested a
memory of the original phenotype presumably because
of a limitation of the reprogramming procedure
[103,104], but interestingly, iPS cell populations with
abnormal gene expression could be coaxed to a more
ES cell-like pattern either by prolonged culture or treat-
ment with small molecules. It has been suggested that
advantage might be taken of this memory by using
donor cells of the tissue type that one ultimately
wishes to produce from the iPS cells. In that way, the
cells produced from the iPS cells might more closely
resemble endogenous cells of the same type as the
donor cells. While superficially attractive, this approach
assumes that the epigenetic memory of the donor phe-
notype is the only failure of reprogramming, whereas a
procedure that fails to reprogramme accurately may
well have other limitations.
Unexpected differences between human ES cell
lines from different laboratories were revealed by simi-
lar analyses [105]. In many cases, iPS cell lines
resembled the ES cell lines from the same laboratory
suggesting that a significant proportion of the variation
was induced by the procedures that were used for the
derivation and maintenance of the cell lines. Together,
these observations suggest that there is a need for refine-
ment not only of the procedures for reprogramming
cells, but also for ES cell derivation and maintenance.
Attainment of these advances will be assisted by a
greater understanding of the mechanisms that underpin
pluripotency.8. USING INDUCED PLURIPOTENT STEM CELLS
TO MODEL HUMAN DISEASE
The ability to produce pluripotent cells from a
patient’s somatic cells has led to the establishment of
iPS cells from many disease conditions including Par-
kinson’s disease and amyotrophic lateral sclerosis
(ALS), also known as motor neuron disease, as dis-
cussed by Unternaehrer & Daley [106] in this issue.
These disease-specific iPS cells are being used in an
unprecedented way to discover the molecular basis of
the inherited disease and to establish assays to identify
small molecules that prevent or delay the development
of disease symptoms. The progress and the likely
challenges can be illustrated in relation to familial dys-
autonomia (FD), ALS, muscle wasting diseases and
diabetes.
As discussed in detail by Lee & Studer [107] in this
issue, the study of FD provides an excellent proof of
the concept that it is possible to use iPS cells and their
derivatives to obtain important insight into the molecular
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where there is little prior knowledge. FD is a rare auto-
somal recessive disease associated with deficiencies of
the autonomic nervous system and dysfunction of
small-fibre sensory neurons. It is caused by single-point
mutation in intron 20 of the I-k-B kinase complex-
associated protein (IKBKAP) gene, which leads to
exon 20 skipping and reduced levels of full-length
IKAP protein (Lee & Studer). IKBKAP is part of the
transcription elongation complex and it is widely
expressed, raising the interesting question of why a
defect in a gene with such wide expression should have
such an exquisitely cell-specific phenotype. There are
no mouse models of the disease.
A number of iPS cell lines were derived from
patients with the disease and their unaffected relatives
with ES cell lines also used as control [108]. IKBKAP
expression was determined in tissues from all three
germ layers: neural crest precursors, neural rosette
cells, haematopoietic cells, endothelial cells and endo-
dermal precursors. The lower absolute level of normal
IKBKAP in all cell types of the patient-derived cells
mimicked the differences in vivo [108]. Microarray
analysis of gene expression in neural crest precursors
revealed decreased expression of several genes con-
cerned with peripheral neurogenesis. In a wound-
healing assay, FD-derived neural crest precursors
migrated less efficiently than control cells. Finally, it
was demonstrated that the plant hormone kinetin
was able to decrease the quantity of mutant protein
and partially restore the level of normal protein, but
long-term treatment was required to restore generation
of autonomic neurons. As the mutation has its effect
during development and very early life, this raises the
practical challenge that full prevention of the disease
symptoms may require treatment during foetal life.
In this project, the cells studied were all precursor
populations and the authors emphasize the need to
extend these studies to the full range of terminally dif-
ferentiated populations as methods for their derivation
become available.
ALS is a relentless progressive family of different, but
related, conditions. The common characteristic is the
death of both upper and lower motor neurons in the
brain stem and the spinal cord. During development
of the disease, the motor neurons accumulate inclusions
that typically contain ubiquitinated proteins, including
TAR DNA-binding protein (TDP43). Approximately
5 per cent of cases are inherited, but the cause of the
vast majority of cases is unknown. Among inherited
cases, approximately 20 per cent are associated with
mutations in superoxide dismutase (SOD1) of which
more than 150 have been identified. Causative
mutations have been identified in several other genes
that are all involved in protein processing [109].
Table 2 describes the known mutations. At present
there are no effective treatments for ALS.
Research with mice carrying mutant human SOD1
transgenes showed that the disease arises from the
presence of a corrupted protein rather than a loss of
function. In a more detailed analysis, removal of the
transgene specifically from motor neurons or glia
showed that onset of the disease is associated with
the mutant gene in the motor neurons, but that fatalPhil. Trans. R. Soc. B (2011)progression of the disease reflected the presence of
the transgene in the glia [145].
In the first laboratory based studies of the disease,
motor neurons and glia were brought together in co-
culture [146–148]. In these cases, the cells were
derivatives of ES cells or of primary cells, and not
iPS cells. The motor neurons were derived from
human ES cells in all studies and they were cultured
with glia that carried a transgene which directs the
expression of a mutant human SOD1 allele. In one
case, the glia were from transgenic mice [147], while
in the other, the cells were primary human astrocytes
transduced with the mutant human gene [148]. Both
groups observed death of motor neurons under these
co-culture conditions, thus mimicking events in vivo.
Inclusion of an antioxidant reduced the incidence of
cell death suggesting that therapies of this kind may
be beneficial and should be investigated further [148].
While these results demonstrate that cell culture can
be used to model some aspects of degeneration in
ALS, a note of caution is necessary because the trans-
gene expressed the mutant protein at a higher than
native level, and in one study expression of the
mutant protein by the native promoter did not cause
the death of neurons in the culture assay that was
used [147]. This highlights the limitations of iPS
cells in this specific context. Ongoing projects in sev-
eral laboratories examine the role of other candidate
genes in the aetiology of ALS. It is now known that
aberrant accumulation of TDP43 occurs in over 90
per cent of cases of ALS, while mutations in this
gene account for only 2 per cent of inherited cases.
It remains to be seen whether novel treatments devel-
oped on the basis of a new understanding of the
causative mechanisms in inherited cases will also be
effective in sporadic cases.
In the paper by Melton [149] in this issue, it has
been proposed that the emerging methods will make
it possible to investigate even more complex diseases
such as type 1 diabetes. In most cases, type 1 diabetes
is an autoimmune disease in which immune cells
attack and deplete the pancreatic beta cells that nor-
mally monitor and maintain blood glucose levels.
While this process is well-documented, the initial trig-
ger that sets off this chain of events is unknown. In
order to study the molecular basis of the disease, pan-
creatic beta cells, thymic epithelia and haematopoietic
stem cells from diabetic patients must be produced
and the relationship between these different cells
must be analysed within immune-deficient mice.
iPS cells offer exciting new possibilities for under-
standing the complex processes that underlie the
initiation and pathology of muscle diseases, as dis-
cussed by Shadrach & Wagers [150] in this issue.
Muscle tissue is unusual in that it is possible to
obtain the specialized muscle-forming stem cells
known as satellite cells in a biopsy. Research using
these cells has established that loss of satellite cell
function can lead to the failure of muscle to recover,
particularly in cases of progressive muscle disease
such as Duchenne muscular dystrophy. Recent pro-
gress in the isolation of muscle satellite cells and
elucidation of the cellular and molecular mediators
controlling their activity indicate that these cells
Table 2. Mutations linked with familial ALS (fALS). ALS, amyotrophic lateral sclerosis; FTD, frontotemporal lobe
dementia; AD, autosomal dominant; AR, autosomal recessive.
familial ALS
designation location of mutation inheritance
no. indentified
mutations
chromosomal
locus onset references
ALS1 SOD1 AD þ120 21q adult [110]
ALS2 ALSIN AR 10 2q33 juvenile [111–114]
ALS3 not established AD not established 18q21 adult [115]
ALS4 SETX AD 3 9q34 juvenile [116,117]
ALS5 not established AR not established 15q15 adult [118]
ALS6 FUS AD/AR 16 16q21 adult [119–121]
ALS7 not established AD not established 20p13 adult [122]
ALS8 VAPB AD 1 20q13.3 adult [123,124]
ALS9 angiogenin/VEGF AD 6 14q11 adult [125–128]
ALS10 TDP43/TARDP AD 30 1q36.2 adult [109,129–135]
ALS-FTD MAPT (Tau) AD þ50 17q21.1 adult [136–139]
FTD3 CHMP2B AD þ6 3 adult [140]
ALS DCTN1 AD 3 2p13 adult [141,142]
ALS OPTN AD .3 10 adult [143]
ALS VCP AD .1 9p13.3 adult [144]
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cell-based therapies may involve either direct cell
replacement or development of drugs that enhance
endogenous muscle repair mechanisms. Ultimately,
the ability to derive transplantable muscle stem cells
from patient-specific iPS cells would make it possible
to create gene-corrected cells that would be genetically
matched to individual patients.
The study of FD and the recent demonstration of
long Q-T syndrome in cardiomyocytes derived from
iPS cells [151] indicate that it is possible to use iPS
cells and their derivatives to characterize the molecular
mechanisms that cause some inherited diseases. It may
be important that the disease phenotype of both of
these conditions is apparent at or soon after birth
and reflects the influence of dominant mutations. By
contrast, more common degenerative diseases such
as Parkinson’s and Alzheimer’s diseases usually
develop over many years and involve effects of several
genes and environmental influences.
There is no absolute requirement for knowledge of
the causative mutation, provided that it is very likely
that the disease was inherited. iPS cells may make it
possible to search for genes that modify the effect of
mutations. These might be identified by contrasting
iPS cells from patients within the same family who
carry the same mutation, but who do not exhibit dis-
ease symptoms as the lack of effect of the mutation
may reflect the influence of genes that are able to ame-
liorate the harmful effect of the mutation. An
understanding of the means by which this occurs
may suggest new approaches to therapy.
The use of reprogrammed cells should be comple-
mented by other approaches to study inherited
diseases, including the use of gene targeting to either
introduce candidate mutations into ES cell lines or
to correct a mutation to confirm its role in causing a
disease phenotype. There is also an opportunity to
request permission to derive ES cells from embryos
that are being discarded because they were identified
by pre-implantation genetic diagnosis as carrying a
mutation that causes a serious inherited disease.Phil. Trans. R. Soc. B (2011)Together, these opportunities hold out the long-term
promise of providing the first effective treatments for
at least some degenerative diseases.9. PRACTICAL CONSIDERATIONS FOR
DEPLOYMENT OF REGENERATIVE STRATEGIES
In the longer term, it may be possible to replace the dead
or non-functioning cells that cause disease symptoms
with healthy, laboratory produced cells. However, a
great number of biological and technical challenges will
have to be overcome before this becomes possible. At
present, clinical trials are in progress in which human
ES cell derivatives are being considered for spinal cord
repair [152] and immortalized foetal neurons are being
developed for the treatment of stroke [153].
One biological challenge is the immune rejection
that may follow transplantation of cells from an unre-
lated embryo or individual. The ability to produce
pluripotent cell lines from an adult by reprogramming
creates the possibility of providing patient-specific cell
lines. However, the effort and cost involved would
probably be prohibitive, and alternative strategies are
suggested by Taylor et al. [154] in this issue. It has
been proposed that banks of appropriately selected
cell lines could provide matched cell lines for a majority
of the population. Similar conclusions were drawn from
analyses in Britain and Japan [155,156] and suggest
that banks of selected iPS cells from blood group O
donors with conserved homozygous human leucocyte
antigen (HLA) haplotypes would be the most effective
way of providing cells for treatment of a majority of the
population. Specifically, it is estimated that around 10
lines that are blood group O and homozygous for
HLA haplotypes would be expected to provide a perfect
HLA-A, -B and -DR match for around 38 per cent of
recipients and be beneficial for 67 per cent of recipients
taken at random [156]. A total of around 150 lines
would provide beneficial lines for essentially the entire
British population. Racial differences could then be
accommodated by exchanging lines between different
countries. It should be noted that the use of such
2192 I. Wilmut et al. Introduction. Evolving biology of cell reprogrammingpartially matched cells would require chronic immune
suppression and thus while valuable for off-the-shelf
therapies at scale, these are not optimal cells. Before
cells can be used for therapy, there is also a need to resolve
a number of other biological issues, none of which are tri-
vial. These include establishing methods for the large-
scale production of clinical grade cells at specific stages
of differentiation, storing and shipping those cells, and
transplanting them to the appropriate location within
the body.
In addition to these biological challenges, novel
approaches are required for funding both the particu-
larly expensive pre-clinical phases of development and
the treatments themselves. As has been emphasized by
Prescott [157] in this issue, regenerative treatments by
cell therapy are more expensive than conventional
pharmacological treatments, but, therapeutic benefits
may last longer and therefore be more cost-effective
in the long term.10. WHAT ARE THE LIMITS TO THE
OPPORTUNITIES TO MODIFY CELL FATE?
Our understanding of the stability of cell phenotype has
been transformed in a totally unexpected manner
during recent decades. The examples of cellular repro-
gramming tell us that cell fate is plainly far less rigidly
determined than was previously believed. However,
the limitations to our opportunities to change cell fate
are still not clear. Is it possible, for instance, to produce
any cell type from any donor cell type, given the intro-
duction of the necessary regulatory molecules and an
appropriate culture environment?
Cell reprogramming has already created extra-
ordinary opportunities for research. In time,
reprogramming studies may offer new drug treatments
that prevent degenerative changes or induce stem or
progenitor cells to differentiate into the affected lin-
eage in a specific condition. Cell transplantation
might also become available for some degenerative dis-
eases. The pace and scope of these advances are clearly
unpredictable. In all likelihood, cell therapy will not be
possible for all degenerative and genetic diseases for
reasons that we cannot yet foresee. Furthermore, the
development of treatments will almost definitely
happen over a period of decades, and not merely
years. Despite these notes of caution, we can be opti-
mistic that the pace of advance will not slacken and
that scientists can hope to deliver the therapeutic
gold that patients so urgently seek.We are grateful to our colleagues, including Tilo Kunath and
Keisuke Kaji, for their contribution to the ideas that are
discussed in this review. We are especially grateful to
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